No Data Yet
Investment analysis firm StockStory identified NeoGenomics (NEO), Hewlett Packard Enterprise (HPE), and KeyCorp (KEY) as stocks to avoid, citing concerns over high debt, declining profitability, and slow growth.
Illumina has made a strategic investment in MyOme to support its Proactive Health Trial, which utilizes whole-genome sequencing to enable proactive healthcare. The collaboration aims to demonstrate significant cost savings and improved patient outcomes, reflecting a broader industry shift toward data-driven, personalized medicine.